SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a massive 20-year lease agreement with Anthropic for its Justified Data campus, signaling a major shift toward long-term AI infrastructure revenue. Community sentiment is largely bullish, with investors viewing the move as validation of the company's transition from a Bitcoin mining proxy into a high-conviction AI compute powerhouse.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is currently generating significant market buzz as traders weigh its role as a stable AI infrastructure backbone against headline-driven volatility. Community members are actively debating the stock's recent price action, often drawing comparisons between Dell's long-term enterprise growth and the higher-risk dynamics of other AI-linked hardware players.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge in trading volume and social sentiment, driven by high short interest and anticipation for the upcoming LivePerson merger integration. Investors are closely monitoring key price thresholds around $7 to gauge if a breakout in momentum can sustain a potential shift toward the double-digit price levels favored by optimistic community members.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is seeing high volatility as investors debate the impact of record-breaking Q2 deliveries against broader concerns about margin sustainability and ongoing autonomous driving expansion. While bulls are energized by the robotaxi rollout in Miami and speculative merger talk, bears are highlighting technical weakness and institutional profit-taking that followed the delivery announcement.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as investors monitor a potential technical breakout, bolstered by institutional accumulation from ARK Invest and growing optimism regarding the company's full-scale digital banking platform. While the community remains divided between bullish long-term growth narratives and frustration over persistent intraday price volatility, discussions are heavily focused on the stock's ability to clear key technical resistance levels ahead of upcoming earnings.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is currently experiencing significant bullish momentum driven by the expansion of its BetterHelp platform insurance coverage and a strategic partnership with Walmart, which investors see as a validator of its long-term telehealth infrastructure. The community is actively debating the potential for a short squeeze as high short interest persists alongside this positive fundamental shift, though long-term holders remain focused on the company's AI-driven scalability and role as a global leader in digital healthcare.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending as investors weigh its turnaround efforts and cost-cutting measures against broader concerns regarding consumer spending and intense sector competition. The community remains divided, with some actively loading long-dated call options in anticipation of a rebound, while others point to macro headwinds and declining retail sentiment as reasons for caution.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is experiencing significant volatility as investors react to the company's unexpected announcement of a large-scale convertible note offering, despite holding a substantial cash position. While management maintains that the capital raise will support pipeline advancement and commercialization, the community is actively debating whether this signals an imminent strategic acquisition, further dilution concerns, or a lack of confidence in near-term revenue growth.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to persistent volatility and intense debate among investors over its long-term potential as an enterprise AI orchestration layer. The community remains sharply divided between those accumulating shares at current levels, citing strong cash reserves and a massive short interest, and those frustrated by the stock's inability to sustain upward momentum amid broader software sector weakness.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing a significant pullback following the unexpected scheduling of an FDA Advisory Committee meeting for Deramiocel just weeks ahead of its PDUFA date, fueling market uncertainty. While the community remains divided between those viewing this as a bearish signal of unresolved efficacy concerns and those who see it as a transparent, politicized opportunity to secure a broader label approval, investors are heavily debating the reliability of the stock's five-year clinical data versus the potential for regulatory delay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Truist⬆️ $IDYA&#39;s PT to $65 from $60 and reiterated at a Buy rating. 
$IMCR $IMTX 
Truist said in its note: 
Today&#39;s disclosure highlights daro&#39;s best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend and mgmt&#39;s comfort provide meaningful derisking signals for the OS outcome (1H27E). 
 
Based on 6.9-mos mPFS and 37% ORR, we believe the daro combo is approvable via the AA pathway and could be used in both HLA-negative and HLA-positive populations. 
 
We project potential approval by YE26/early-2027, assuming a relatively aggressive regulatory timeline which could ultimately unlock our $800M+ peak revenue potential in MUM (and ~$1.7B across settings). 
 
Assigning a higher PoS, we raise our PT to $65 (from $60) and reiterate Buy.

Stocks HTS

Alan Purdie

Mizuho reiterated $IDYA Outperform/$46 
$IMCR $REPL IMTX  
Mizuho said—Yesterday, IDYA announced a slight shift in the expected timing of its top-line data release from the P2/3 OptimUM-02 study for lead asset darovasertib/daro in metastatic uveal melanoma/mUM. 
 
With a database lock, according to IDYA, now expected in the first half of April, we believe the data will now come in the May timeline. While this perhaps comes as a slight disappointment (recall prior guidance on expected timing was late March), given knowledge that the OptiMUM-02 study is event-driven, we&#39;re not overly concerned on potential implications on the data outcome. 
As such, we maintain our OP rating on IDYA. 
 
Should shares come under pressure today on a perception yesterday&#39;s announced delay might infer an increased chance of a potentially negative P2/3 data outcome, we recommend being opportunistic on weakness.

StockTwits Web

Ideaya Biosciences Inc

Immunocore Holdings PLC - ADR

Replimune Group Inc

Quantumup

RBC Capital y&#39;day⬆️the PT on $IDYA to $53 from $49 and reiterated at an Outperform rating. 
$IMCR $IMTX 
RBC Capital said in its note: 
Following successful topline ph.II/III data in HLA- mUM this morning, we had a chance to catch up with management, and we remain positive on the meaningfulness of IDYA&#39;s data, their regulatory strategy for daro&#39;s NDA filing in 2H26, and commercial positioning into a &#39;27 launch. 
 
Doc feedback suggests significant enthusiasm for use, favorable read-throughs to other indications, and we think the ultimate OS readout is also likely to come in positive. 
 
We see no red flags, and with today&#39;s ~6% upside not fully reflecting the strength of the data and modest estimates in the mUM market, we remain buyers.

Immatics N.V

's PT to $65 from $60 and reiterated at a Buy rating. 


 
Truist said in its note: 
Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend and mgmt's comfort provide meaningful derisking signals for the OS outcome (1H27E). 
 
Based on 6.9-mos mPFS and 37% ORR, we believe the daro combo is approvable via the AA pathway and could be used in both HLA-negative and HLA-positive populations. 
 
We project potential approval by YE26/early-2027, assuming a relatively aggressive regulatory timeline which could ultimately unlock our $800M+ peak revenue potential in MUM (and ~$1.7B across settings). 
 
Assigning a higher PoS, we raise our PT to $65 (from $60) and reiterate Buy.